아미노필린 시장 예측 : 투여 경로별, 유통 채널별, 용도별, 지역별(-2030년)

According to Stratistics MRC, the Global Aminophylline Market is accounted for $299.3 million in 2024 and is expected to reach $353.2 million by 2030 growing at a CAGR of 2.8% during the forecast period. Aminophylline is a bronchodilator used to treat asthma, chronic bronchitis, and other respiratory conditions by relaxing airway muscles and improving breathing. The aminophylline market is used in hospitals, clinics, and homecare settings, driven by the rising prevalence of respiratory diseases and growing healthcare needs. It can be administered orally, intravenously, or as an injection and requires careful dosage monitoring due to its narrow therapeutic range.

According to World Health Organization (WHO) data, respiratory diseases are a leading cause of death globally. Similarly, a 2023 article in the Economic Times highlighted a global increase in asthma cases, affecting approximately 339 million individuals.

Market Dynamics:

Driver:

Growing aging population

The growing aging population is a significant driver for the aminophylline market. As people age, they are more likely to develop chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). Aminophylline, a bronchodilator, is commonly used to manage these conditions by relaxing the muscles in the airways and improving breathing. The increasing number of elderly individuals, who are more susceptible to respiratory disorders, drives the demand for aminophylline, thereby contributing to market growth.

Restraint:

Stringent regulatory requirements

Stringent regulatory requirements pose a significant restraint on the aminophylline market. The approval process for pharmaceuticals, including aminophylline, involves rigorous testing and compliance with safety and efficacy standards set by regulatory bodies such as the FDA and EMA. These stringent regulations can lead to delays in product approvals and increased costs for manufacturers. The need to adhere to these complex regulatory frameworks can hinder the timely introduction of new aminophylline formulations, thereby restraining market growth.

Opportunity:

Increasing prevalence of respiratory disorders

The increasing prevalence of respiratory disorders presents a substantial opportunity for the aminophylline market. Conditions such as asthma, COPD, and bronchitis are becoming more common due to factors like pollution, smoking, and lifestyle changes. Aminophylline is an effective treatment for these conditions, helping to alleviate symptoms and improve quality of life. The rising incidence of respiratory disorders drives the demand for aminophylline, creating opportunities for market expansion and the development of new therapeutic formulations.

Threat:

Side effects and safety concerns

Side effects and safety concerns associated with aminophylline use pose a threat to the market. Common side effects include nausea, vomiting, headaches, and insomnia, while severe reactions can include irregular heartbeats and seizures. These adverse effects can limit the use of aminophylline, as patients and healthcare providers may opt for alternative treatments with fewer risks. Addressing these safety concerns through improved formulations and patient education is crucial to maintaining market growth.

Covid-19 Impact:

The Covid-19 pandemic had a mixed impact on the aminophylline market. While the focus on respiratory health increased the demand for treatments like aminophylline, disruptions in supply chains and healthcare services affected production and distribution. The pandemic highlighted the importance of effective respiratory treatments, potentially driving future demand for aminophylline as healthcare systems recover and prioritize respiratory care.

The oral segment is expected to be the largest during the forecast period

The oral segment is anticipated to dominate the aminophylline market due to its convenience and widespread use. Oral administration of aminophylline, in the form of tablets or capsules, is preferred by patients for its ease of use and non-invasive nature. This segment's growth is driven by the increasing prevalence of chronic respiratory conditions and the preference for oral medications, which offer consistent dosing and improved patient compliance.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

The online pharmacies segment is projected to have the highest CAGR due to the growing trend of digital healthcare and e-commerce. The convenience of purchasing medications online, coupled with the increasing use of digital platforms for healthcare services, drives the growth of this segment. Online pharmacies offer easy access to aminophylline, especially for patients in remote areas or those seeking discreet purchasing options, contributing to the segment's rapid expansion.

Region with largest share:

North America is positioned to dominate the aminophylline market due to its advanced healthcare infrastructure and high prevalence of respiratory disorders. The region's well-established medical research facilities and strong focus on innovative treatments drive the demand for aminophylline. Additionally, the presence of major pharmaceutical companies and substantial healthcare expenditure further bolster North America's leading position in the market.

Region with highest CAGR:

The Asia Pacific region anticipates rapid growth in the aminophylline market, driven by increasing urbanization, rising pollution levels, and a growing aging population. Countries like China and India are experiencing a surge in respiratory disorders, boosting the demand for effective treatments like aminophylline. Government initiatives to improve healthcare infrastructure and the expansion of pharmaceutical manufacturing capabilities contribute to the high CAGR in the Asia Pacific region.

Key players in the market

Some of the key players in Aminophylline Market include GlaxoSmithKline plc, Altor BioScience Corporation, Ono Pharmaceutical, Bayer AG, Teva Pharmaceutical Industries Ltd., Biosynth, Pfizer Inc., Abcam plc, Henry Schein, Inc., Medline Industries, Inc., Boehringer Ingelheim, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co., Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd. and Zydus Cadila.

Key Developments:

In May 2024, Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Theophylline Extended-Release Tablets, 300 mg and 450 mg (USRLD: Theo-Dur Extended-Release Tablets). Theophylline is used to treat asthma and chronic obstructive pulmonary disease (COPD). The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, India.

In January 2023, Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announces that the US Food and Drug Administration (FDA) has approved AstraZeneca's Airsupra (albuterol/budesonide, formerly known as PT027) for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.

Route of Administrations Covered:

• Oral
• Intravenously
• Injections

Distribution Channels Covered:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Retail Pharmacies
• Online Pharmacies

Applications Covered:

• Asthma Treatment
• Chronic Obstructive Pulmonary Disease (COPD) Treatment
• Infant Apnea
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Aminophylline Market, By Route of Administration

• 5.1 Introduction
• 5.2 Oral
• 5.3 Intravenously
• 5.4 Injections

6 Global Aminophylline Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Ambulatory Surgical Centers
• 6.5 Retail Pharmacies
• 6.6 Online Pharmacies

7 Global Aminophylline Market, By Application

• 7.1 Introduction
• 7.2 Asthma Treatment
• 7.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment
• 7.4 Infant Apnea
• 7.5 Other Applications

8 Global Aminophylline Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 GlaxoSmithKline plc
• 10.2 Altor BioScience Corporation
• 10.3 Ono Pharmaceutical
• 10.4 Bayer AG
• 10.5 Teva Pharmaceutical Industries Ltd.
• 10.6 Biosynth
• 10.7 Pfizer Inc.
• 10.8 Abcam plc
• 10.9 Henry Schein, Inc.
• 10.10 Medline Industries, Inc.
• 10.11 Boehringer Ingelheim
• 10.12 Novartis AG
• 10.13 Sanofi S.A.
• 10.14 AstraZeneca plc
• 10.15 Merck & Co., Inc.
• 10.16 Mylan N.V.
• 10.17 Sun Pharmaceutical Industries Ltd.
• 10.18 Cipla Ltd.
• 10.19 Dr. Reddy's Laboratories Ltd.
• 10.20 Zydus Cadila